A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.
Epistemonikos ID: 33b64570d514bcc70d0f1012148a378843fdb476
First added on: May 07, 2024